Skip to main content
main-content

29-09-2020 | Gastrointestinal cancer | Video

ESMO 2020 | Advanced gastroesophageal cancer survival benefit with first-line nivolumab

Markus Moehler describes the CheckMate 649 trial findings showing improved survival outcomes with the combination of first-line nivolumab and chemotherapy for individuals with advanced gastric, gastroesophageal junction and esophageal cancers (7:02).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits